Huntington’s Disease

Welcome to the survey activity

Teva recently conducted a research survey among the general population in the United States to estimate the impact of chorea associated with Huntington’s disease (HD) on quality of life.

The survey asked them to consider different severities of chorea and asked how many years of life they were willing to give up to live in full health. The responses from the survey were used to calculate utility values, which are used to help assess the burden of Huntington’s disease. To date, no studies have reported utility values specifically for HD chorea. Our aim was to increase understanding of the condition and highlight what it would be like to live with HD chorea.

In this interactive short activity, you will be shown a scenario and then asked a series of short questions based on the survey. You can then see how people who took the survey responded and also view the poster with the survey results. You can view the poster at any time by clicking the link at the top of the screen.

Please select a scenario and press continue.
Or click on the random scenario generator and one will be selected for you.

Scenario 1 Severe chorea
Scenario 2 Moderate to severe chorea
Scenario 3 Mild to moderate chorea
Scenario 4 Mild chorea

Utility values

Close

Utilities are values that reflect an individual’s preferences for different health outcomes and reflect societal perceived disease severity. They are typically measured on a scale, with zero reflecting states of health equivalent to death and one reflecting perfect health. They are used by decision-makers to more accurately assess treatment benefit.

References: What_are_health_util.pdf (bandolier.org.uk) 2021 American Academy of Neurology Abstract Website (mirasmart.com) (Claassen et al AAN 2021)

HD References

Close

Primary References

AAN 2021 HD Utility Encore Poster

Additional References
1. Bates GP, et al. Nat Rev Dis Primers. 2015;1:15005.
2. Ross CA, et al. Nat Rev Neurol. 2014;10(4):204-216.
3. Thorley EM, et al. Patient. 2018;11(5):547-559.
4. Ho AK, et al. Clin Genet. 2011;80(3):235-239.
5. Hawton A, et al. Eur J Health Econ. 2019;20(9):1335-1347.
6. van Walsem MR, et al. Health Qual Life Outcomes. 2017;15(1):6.
7. Dorey J, et al. J Mark Access Health Policy. 2016;4.
8. Bleichrodt H, Johannesson M. J Health Econ. 1997;16(2):155-175.
9. Bleichrodt H. Health Econ. 2002;11(5):447-456.
10. van Osch SM, et al. Med Decis Making. 2004;24(5):511-517.
11. Wright DR, et al. Pharmacoeconomics. 2009;27(9):713-723.
12. What_are_health_util.pdf (bandolier.org.uk)
13. 2021 American Academy of Neurology Abstract Website (mirasmart.com) (Claassen et al AAN 2021)